Overview
NEOsphere Biotechnologies provides a proteomics-based platform for targeted protein degradation (TPD) drug discovery, enabling high-throughput characterization and optimization of degrader compounds. Their technology offers proteome-wide screening, precise quantification, and rapid turnaround to identify novel targets and advance programs. Based in Munich, Germany, they partner with pharma companies like Kymera Therapeutics to accelerate TPD development.
Frequently asked questions
- What capabilities does NEOsphere offer for targeted protein degradation?
- NEOsphere provides a target- and E3-agnostic proteomics platform for high-throughput screening of degrader compounds, target identification, compound optimization, and proteome-wide analysis with neoVERSE data tools.
- What are NEOsphere's regulatory and quality standards?
- As a biotech founded in 2022 specializing in mass spectrometry proteomics, NEOsphere demonstrates scientific excellence through publications in top-tier journals, supporting rigorous drug discovery standards.
- Where does NEOsphere operate and serve clients?
- NEOsphere Biotechnologies is based in Munich, Germany, and collaborates globally with partners like Kymera Therapeutics to advance TPD programs in pharma and biotech.